Sun-Ae Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sun-Ae Park has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Lee Kyung Kim
Laboratory of Pharmacoimmunology, Integrated Research Institute of Pharmaceutical Sciences and BK21 FOUR Team for Advanced Program for Smart Pharma Leaders, College of Pharmacy The Catholic University of Korea Bucheon South Korea
6 shared publications - Tae-Hwe Heo
College of Pharmacy, The Catholic University of Korea, Bucheon, Gyeonggi-Do, Republic of Korea
6 shared publications - Hee Jung Kim
Affiliation Laboratory of Pharmacoimmunology, Integrated Research Institute of Pharmaceutical Sciences and BK21 FOUR Team for Advanced Program for Smart Pharma Leaders, College of Pharmacy, The Catholic University of Korea, Bucheon-si, Gyeonggi-do, Republic of Korea
5 shared publications - Hae-Ri Lee
Laboratory of Pharmacoimmunology, Integrated Research Institute of Pharmaceutical Sciences and BK21 FOUR Team for Advanced Program for Smart Pharma Leaders, College of Pharmacy The Catholic University of Korea Bucheon South Korea
2 shared publications - Young Tae Kim
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
2 shared publications - Aeri Park
Laboratory of Pharmacoimmunology, Integrated Research Institute of Pharmaceutical Sciences and BK21 FOUR Team for Advanced Program for SmartPharma Leaders, College of Pharmacy, The Catholic University of Korea, 43 Jibong-ro, Bucheon-si, Gyeonggi-do 14662, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 11 August 2026
- Published by Elsevier in SSRN Electronic Journal
LDLR knockout and TNF overexpression accelerate severe atherosclerosis in aged mice
Background and aims: We have previously shown that TNF and senescence induced vascular leaking syndrome and that adding an anti-tumor necrosis factor (TNF) agent to conventional therapy (pravastatin and sarpogrelate) is required to achieve a synergistic effect in the treatment of atherosclerosis in low-density lipoprotein receptor (LDLR) knockout (KO) mice. However, the direct contribution of TNF to the development of atherosclerosis in old age remains unclear. In this study, we investigated the complex pathophysiology of atherosclerosis development by lipid and TNF at old age, so we created a novel animal model (LAT mice), which was crossed with LDLR KO atherosclerosis mice and TNF overexpression transgenic (TNF TG) mice with a high-fat diet (HFD).Methods: Ten-week-old C57BL/6, TNF KO, TNF TG, LDLR KO, and LDLR KO × TNF TG (LAT) mice were fed an HFD for 40 weeks. Body weight, lipids, inflammatory cytokines, Th17/Treg cells, and monocyte/macrophage cells were analyzed. Atherosclerotic plaques in the aortas and aortic roots were quantified by staining them with Oil Red O.Results: The atherosclerotic plaques in the LAT mice were significantly increased compared to those in the LDLR KO mice. The LAT mice also showed higher upregulation of ICAM-1, MOMA-2, Th17 cells, inflammatory cytokines (IL-1β, IL-6, IL-17A), and LDL cholesterol than the LDLR KO mice.Conclusions: Our results suggest that TNF-induced inflammation plays a dysfunctional role in promoting atherosclerotic plaque formation by increasing adhesion molecules, recruiting macrophages, and elevating inflammatory cytokines and Th17 cells. Thus, TNF can play a critical inductive role in the development of atherosclerosis in mice. An anti-TNF inhibitory strategy may have immunotherapeutic implications for older patients with atherosclerosis.
- 11 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessLDLR knockout and TNF overexpression accelerate severe atherosclerosis in aged mice
Background and aims: We have previously shown that TNF and senescence induced vascular leaking syndrome and that adding an anti-tumor necrosis factor (TNF) agent to conventional therapy (pravastatin and sarpogrelate) is required to achieve a synergistic effect in the treatment of atherosclerosis in low-density lipoprotein receptor (LDLR) knockout (KO) mice. However, the direct contribution of TNF to the development of atherosclerosis in old age remains unclear. In this study, we investigated the complex pathophysiology of atherosclerosis development by lipid and TNF at old age, so we created a novel animal model (LAT mice), which was crossed with LDLR KO atherosclerosis mice and TNF overexpression transgenic (TNF TG) mice with a high-fat diet (HFD).Methods: Ten-week-old C57BL/6, TNF KO, TNF TG, LDLR KO, and LDLR KO × TNF TG (LAT) mice were fed an HFD for 40 weeks. Body weight, lipids, inflammatory cytokines, Th17/Treg cells, and monocyte/macrophage cells were analyzed. Atherosclerotic plaques in the aortas and aortic roots were quantified by staining them with Oil Red O.Results: The atherosclerotic plaques in the LAT mice were significantly increased compared to those in the LDLR KO mice. The LAT mice also showed higher upregulation of ICAM-1, MOMA-2, Th17 cells, inflammatory cytokines (IL-1β, IL-6, IL-17A), and LDL cholesterol than the LDLR KO mice.Conclusions: Our results suggest that TNF-induced inflammation plays a dysfunctional role in promoting atherosclerotic plaque formation by increasing adhesion molecules, recruiting macrophages, and elevating inflammatory cytokines and Th17 cells. Thus, TNF can play a critical inductive role in the development of atherosclerosis in mice. An anti-TNF inhibitory strategy may have immunotherapeutic implications for older patients with atherosclerosis.
- Open Access
- 28 July 2025
- Published by Wiley in British Journal of Pharmacology
- Vol. 182 (22) , 5670-5689
IA‐0130, a novel 3‐(1,3‐diarylallylidene)oxindole derivative, alleviates ovarian cancer via inhibiting IL‐6/gp130/STAT3 signalling
Background and Purpose: Dysregulation of the IL‐6/glycoprotein 130(gp130)/STAT3 signalling axis is implicated in several human diseases, particularly cancer. Notably, gp130, a single transducer of this signalling axis, is a target for ovarian cancer treatment. However, data regarding small‐molecule inhibitors of gp130 are lacking. Therefore, we aimed to identify a 3‐(1,3‐diarylallylidene)oxindole derivative that binds gp130 and reveal the anticancer mechanism acting on the IL‐6/gp130/STAT3 pathway in ovarian cancer. Experimental Approach: We synthesised 24 derivatives based on the scaffold of 3‐(1,3‐diarylallylidene)oxindole, and derivatives that inhibit IL‐6 signalling were selected using HEK‐Blue™ IL‐6 cells. The binding of derivatives to gp130 was assessed using surface plasmon resonance. IA‐0130, with a strong gp130‐binding ability, was selected to observe its effect on the migration, invasion, cell cycle arrest and apoptosis of ovarian cancer cells in comparison to bazedoxifene, a known gp130‐binding derivative. Additionally, we examined the mechanism underlying the tumour suppressive effect of IA‐0130 in vivo. Key Results: We found that IA‐0130 inhibited gp130/STAT3 phosphorylation in a concentration‐dependent manner in ovarian cancer cell line and also in ovarian cancer‐resistant cell line. By suppressing the expression of downstream target genes, IA‐0130 inhibited cancer cell growth, metastasis, and invasion and induced apoptosis, exhibiting anticancer effects. In a mouse xenograft model of human ovarian cancer, oral administration of IA‐0130 significantly delayed tumour growth. Conclusions and Implications IA‐0130 inhibits tumour growth, migration and metastasis by inhibiting IL‐6/gp130/STAT3 signalling in ovarian cancer by binding gp130. IA‐0130 holds therapeutic potential for treating ovarian cancer as well as anticancer drug‐resistant ovarian cancer.
- 28 July 2025
- Published by Wiley in British Journal of Pharmacology
- Vol. 182 (22) , 5670-5689
Open AccessIA‐0130, a novel 3‐(1,3‐diarylallylidene)oxindole derivative, alleviates ovarian cancer via inhibiting IL‐6/gp130/STAT3 signalling
Background and Purpose: Dysregulation of the IL‐6/glycoprotein 130(gp130)/STAT3 signalling axis is implicated in several human diseases, particularly cancer. Notably, gp130, a single transducer of this signalling axis, is a target for ovarian cancer treatment. However, data regarding small‐molecule inhibitors of gp130 are lacking. Therefore, we aimed to identify a 3‐(1,3‐diarylallylidene)oxindole derivative that binds gp130 and reveal the anticancer mechanism acting on the IL‐6/gp130/STAT3 pathway in ovarian cancer. Experimental Approach: We synthesised 24 derivatives based on the scaffold of 3‐(1,3‐diarylallylidene)oxindole, and derivatives that inhibit IL‐6 signalling were selected using HEK‐Blue™ IL‐6 cells. The binding of derivatives to gp130 was assessed using surface plasmon resonance. IA‐0130, with a strong gp130‐binding ability, was selected to observe its effect on the migration, invasion, cell cycle arrest and apoptosis of ovarian cancer cells in comparison to bazedoxifene, a known gp130‐binding derivative. Additionally, we examined the mechanism underlying the tumour suppressive effect of IA‐0130 in vivo. Key Results: We found that IA‐0130 inhibited gp130/STAT3 phosphorylation in a concentration‐dependent manner in ovarian cancer cell line and also in ovarian cancer‐resistant cell line. By suppressing the expression of downstream target genes, IA‐0130 inhibited cancer cell growth, metastasis, and invasion and induced apoptosis, exhibiting anticancer effects. In a mouse xenograft model of human ovarian cancer, oral administration of IA‐0130 significantly delayed tumour growth. Conclusions and Implications IA‐0130 inhibits tumour growth, migration and metastasis by inhibiting IL‐6/gp130/STAT3 signalling in ovarian cancer by binding gp130. IA‐0130 holds therapeutic potential for treating ovarian cancer as well as anticancer drug‐resistant ovarian cancer.
- Open Access
- 27 March 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (4) , 1018
LncRNA SNHG4 Modulates EMT Signal and Antitumor Effects in Endometrial Cancer through Transcription Factor SP-1
Long non-coding RNAs (lncRNAs) are implicated in the initiation and progression of a variety of tumors, including endometrial cancer. However, the mechanisms of lncRNA in endometrial cancer formation and progression remain largely unknown. In this study, we confirmed that the lncRNA SNHG4 is upregulated in endometrial cancer and correlates with lower survival rates in endometrial cancer patients. Knock-down of SNHG4 significantly reduced cell proliferation, colonization, migration, and invasion in vitro, as well as modulating the cell cycle and reduced tumor growth of endometrial cancer in vivo. In addition, the effect of SNHG4 by the transcription factor SP-1 was confirmed in vitro. We found in this study that SNHG4/SP-1 plays an important role in endometrial cancer progression and may be used as a potential therapeutic and prognostic biomarker for endometrial cancer.
- 27 March 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (4) , 1018
Open AccessLncRNA SNHG4 Modulates EMT Signal and Antitumor Effects in Endometrial Cancer through Transcription Factor SP-1
Long non-coding RNAs (lncRNAs) are implicated in the initiation and progression of a variety of tumors, including endometrial cancer. However, the mechanisms of lncRNA in endometrial cancer formation and progression remain largely unknown. In this study, we confirmed that the lncRNA SNHG4 is upregulated in endometrial cancer and correlates with lower survival rates in endometrial cancer patients. Knock-down of SNHG4 significantly reduced cell proliferation, colonization, migration, and invasion in vitro, as well as modulating the cell cycle and reduced tumor growth of endometrial cancer in vivo. In addition, the effect of SNHG4 by the transcription factor SP-1 was confirmed in vitro. We found in this study that SNHG4/SP-1 plays an important role in endometrial cancer progression and may be used as a potential therapeutic and prognostic biomarker for endometrial cancer.
- Open Access
- 23 March 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (7) , 6038
Butein Inhibits Cell Growth by Blocking the IL-6/IL-6Rα Interaction in Human Ovarian Cancer and by Regulation of the IL-6/STAT3/FoxO3a Pathway
Butea monosperma (Fabaceae) has been used in traditional Indian medicine to treat a variety of ailments, including abdominal tumors. We aimed to investigate the anti-IL-6 activity of butein in ovarian cancer and elucidate the underlying molecular mechanisms. Butein was isolated and identified from B. monosperma flowers, and the inhibition of IL-6 signaling was investigated using the HEK-Blue™ IL-6 cell line. The surface plasmon resonance assay was used to estimate the binding of butein to IL-6, IL-6Rα, and gp130. After treatment with butein, ovarian cancer cell migration, apoptosis, and tumor growth inhibition were evaluated in vitro and in vivo. Furthermore, we used STAT3 siRNA to identify the mechanistic effects of butein on the IL-6/STAT3/FoxO3a pathway. Butein suppressed downstream signal transduction through higher binding affinity to IL-6. In ovarian cancer, butein inhibited cell proliferation, migration, and invasion, and induced cell cycle arrest and apoptosis. In addition, it decreased the growth of ovarian cancer cells in xenograft tumor models. Butein inhibited STAT3 phosphorylation and induced FoxO3a accumulation in the nucleus by inhibiting IL-6 signaling. The anticancer activity of butein was mediated by blocking the IL-6/IL-6Rα interaction and suppressing IL-6 bioactivity via interfering with the IL-6/STAT3/FoxO3a pathway.
- 23 March 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (7) , 6038
Open AccessButein Inhibits Cell Growth by Blocking the IL-6/IL-6Rα Interaction in Human Ovarian Cancer and by Regulation of the IL-6/STAT3/FoxO3a Pathway
Butea monosperma (Fabaceae) has been used in traditional Indian medicine to treat a variety of ailments, including abdominal tumors. We aimed to investigate the anti-IL-6 activity of butein in ovarian cancer and elucidate the underlying molecular mechanisms. Butein was isolated and identified from B. monosperma flowers, and the inhibition of IL-6 signaling was investigated using the HEK-Blue™ IL-6 cell line. The surface plasmon resonance assay was used to estimate the binding of butein to IL-6, IL-6Rα, and gp130. After treatment with butein, ovarian cancer cell migration, apoptosis, and tumor growth inhibition were evaluated in vitro and in vivo. Furthermore, we used STAT3 siRNA to identify the mechanistic effects of butein on the IL-6/STAT3/FoxO3a pathway. Butein suppressed downstream signal transduction through higher binding affinity to IL-6. In ovarian cancer, butein inhibited cell proliferation, migration, and invasion, and induced cell cycle arrest and apoptosis. In addition, it decreased the growth of ovarian cancer cells in xenograft tumor models. Butein inhibited STAT3 phosphorylation and induced FoxO3a accumulation in the nucleus by inhibiting IL-6 signaling. The anticancer activity of butein was mediated by blocking the IL-6/IL-6Rα interaction and suppressing IL-6 bioactivity via interfering with the IL-6/STAT3/FoxO3a pathway.
- Open Access
- 13 August 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (16) , 8693
Bazedoxifene, a GP130 Inhibitor, Modulates EMT Signaling and Exhibits Antitumor Effects in HPV-Positive Cervical Cancer
Persistent HPV (Human Papillomavirus) infection is the primary cause of cervical cancer. Despite the development of the HPV vaccine to prevent infections, cervical cancer is still a fatal malignant tumor and metastatic disease, and it is often difficult to treat, so a new treatment strategy is needed. The FDA-approved drug Bazedoxifene is a novel inhibitor of protein–protein interactions between IL-6 and GP130. Multiple ligand simultaneous docking and drug repositioning approaches have demonstrated that an IL-6/GP130 inhibitor can act as a selective estrogen modulator. However, the molecular basis for GP130 activation in cervical cancer remains unclear. In this study, we investigated the anticancer properties of Bazedoxifene in HPV-positive cervical cancer cells. In vitro and in vivo experiments showed that Bazedoxifene inhibited cell invasion, migration, colony formation, and tumor growth in cervical cancer cells. We also confirmed that Bazedoxifene inhibits the GP130/STAT3 pathway and suppresses the EMT (Epithelial-mesenchymal transition) sub-signal. Thus, these data not only suggest a molecular mechanism by which the GP130/STAT3 pathway may promote cancer, but also may provide a basis for cervical cancer replacement therapy.
- 13 August 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (16) , 8693
Open AccessBazedoxifene, a GP130 Inhibitor, Modulates EMT Signaling and Exhibits Antitumor Effects in HPV-Positive Cervical Cancer
Persistent HPV (Human Papillomavirus) infection is the primary cause of cervical cancer. Despite the development of the HPV vaccine to prevent infections, cervical cancer is still a fatal malignant tumor and metastatic disease, and it is often difficult to treat, so a new treatment strategy is needed. The FDA-approved drug Bazedoxifene is a novel inhibitor of protein–protein interactions between IL-6 and GP130. Multiple ligand simultaneous docking and drug repositioning approaches have demonstrated that an IL-6/GP130 inhibitor can act as a selective estrogen modulator. However, the molecular basis for GP130 activation in cervical cancer remains unclear. In this study, we investigated the anticancer properties of Bazedoxifene in HPV-positive cervical cancer cells. In vitro and in vivo experiments showed that Bazedoxifene inhibited cell invasion, migration, colony formation, and tumor growth in cervical cancer cells. We also confirmed that Bazedoxifene inhibits the GP130/STAT3 pathway and suppresses the EMT (Epithelial-mesenchymal transition) sub-signal. Thus, these data not only suggest a molecular mechanism by which the GP130/STAT3 pathway may promote cancer, but also may provide a basis for cervical cancer replacement therapy.
- 30 June 2021
- Published by International Next-Generation Convergence Technology Association in The Journal of Next-generation Convergence Technology Association
- Vol. 5 (3) , 354-365
A Study on the Priority Decision for Improvement of the Agricultural Management Ledger System
청년창업농 선발 및 영농정착 지원사업 시행 지침에 따라 농림수산식품교육문화정보원이 개발한 경영장 부 프로그램을 활용하여 경영장부를 기록해야 하는 것이 의무화되었다. 본 논문에서는 데이터를 활용한 과학적인 영농활동과 회계장부 관리 등 농업 경영 효율화를 지원하기 위한 시스템인 농업경영장부 시스템에 대해 농업경영 장부 사용자 대상 설문조사 및 전문가 의견수렴 결과를 통해 현황 및 문제점을 분석하고 개선요인을 도출하였다. 그 후 AHP 분석 기법을 활용하여 전문가 대상 설문을 시행하고 결과를 분석하여 농업경영장부 시스템 개선 우선 순위를 도출하여 제안하였다.
- 30 June 2021
- Published by International Next-Generation Convergence Technology Association in The Journal of Next-generation Convergence Technology Association
- Vol. 5 (3) , 354-365
A Study on the Priority Decision for Improvement of the Agricultural Management Ledger System
청년창업농 선발 및 영농정착 지원사업 시행 지침에 따라 농림수산식품교육문화정보원이 개발한 경영장 부 프로그램을 활용하여 경영장부를 기록해야 하는 것이 의무화되었다. 본 논문에서는 데이터를 활용한 과학적인 영농활동과 회계장부 관리 등 농업 경영 효율화를 지원하기 위한 시스템인 농업경영장부 시스템에 대해 농업경영 장부 사용자 대상 설문조사 및 전문가 의견수렴 결과를 통해 현황 및 문제점을 분석하고 개선요인을 도출하였다. 그 후 AHP 분석 기법을 활용하여 전문가 대상 설문을 시행하고 결과를 분석하여 농업경영장부 시스템 개선 우선 순위를 도출하여 제안하였다.
- Open Access
Long Noncoding RNA E2F4as Promotes Progression and Predicts Patient Prognosis in Human Ovarian Cancer
(1) Background: LncRNAs could be a promising biomarker to predict the prognosis of various cancers. The significance of E2F4antisense lncRNA remains unclear in cancer. In this study, we examined the expression level of E2F4as in the serum of ovarian cancer patients and the functional role of E2F4as. (2) Methods: Serum samples were obtained from 108 OC patients and 32 normal patients to measure the expression of E2F4as in the serum. Ovarian cancer cells were used to investigate the role of E2F4as in cell proliferation, invasion, migration and apoptosis, and the expression of E2F4as was knocked down using RNA interference. In addition, E2F4as knockdown cell lines were used in in vivo experiments. (3) Results: The expression of E2F4as was significantly higher in the serum of OC patients than in that of control patients (p < 0.05). The knockdown of E2F4as in ovarian cancer cells led to a decrease in cell proliferation, invasion and migration and an increase in apoptosis. E2F4as knockdown also reduced the expression of epithelium–mesenchymal metastasis (EMT) genes. (4) Conclusion: These findings highlight the clinical significance of E2F4as in predicting the prognosis of OC patients and suggest its potential in promoting tumour aggressiveness by the regulation of EMT-related mechanisms.
Open AccessLong Noncoding RNA E2F4as Promotes Progression and Predicts Patient Prognosis in Human Ovarian Cancer
(1) Background: LncRNAs could be a promising biomarker to predict the prognosis of various cancers. The significance of E2F4antisense lncRNA remains unclear in cancer. In this study, we examined the expression level of E2F4as in the serum of ovarian cancer patients and the functional role of E2F4as. (2) Methods: Serum samples were obtained from 108 OC patients and 32 normal patients to measure the expression of E2F4as in the serum. Ovarian cancer cells were used to investigate the role of E2F4as in cell proliferation, invasion, migration and apoptosis, and the expression of E2F4as was knocked down using RNA interference. In addition, E2F4as knockdown cell lines were used in in vivo experiments. (3) Results: The expression of E2F4as was significantly higher in the serum of OC patients than in that of control patients (p < 0.05). The knockdown of E2F4as in ovarian cancer cells led to a decrease in cell proliferation, invasion and migration and an increase in apoptosis. E2F4as knockdown also reduced the expression of epithelium–mesenchymal metastasis (EMT) genes. (4) Conclusion: These findings highlight the clinical significance of E2F4as in predicting the prognosis of OC patients and suggest its potential in promoting tumour aggressiveness by the regulation of EMT-related mechanisms.